著者
Tadashi Maeda Katsuhito Kashiwagi Sadako Yoshizawa Takahiro Sato Kotaro Aoki Yoshikazu Ishii Kazuhiro Tateda
出版者
National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee
雑誌
Japanese Journal of Infectious Diseases (ISSN:13446304)
巻号頁・発行日
vol.74, no.6, pp.560-562, 2021-11-22 (Released:2021-11-22)
参考文献数
7
被引用文献数
4

Most coronavirus disease 2019 (COVID-19) cases are mild or asymptomatic, and a substantial minority of patients have severe or critical diseases. There are several reports on the potential risk factors of severe disease, but few reports have reported a relationship between antibody titer and severity in Japan. Antibody-dependent enhancement affects disease progression. We evaluated the IgG responses in COVID-19 patients at our tertiary hospital. The IgG index was the measure of interest. We assigned 1.4 as the cutoff value for a positive result based on the specifications by the manufacturer and observed that patients could be categorized into two groups: the early elevation of IgG and late elevation of IgG (IgG elevated in the first 7 days ± 2 days or more than 10 days after symptom onset) groups. The former comprised early IgG responders (n = 7) and the latter comprised late IgG responders (n = 14), and they were compared. The C-reactive protein and D-dimer concentrations were significantly higher in the early IgG responders on admission (HD 0). The respiratory rate was also higher. The lymphocytes were significantly fewer on day 7 of hospitalization (HD 7). These results suggest that early production of anti-severe acute respiratory syndrome coronavirus 2 IgG may be associated with clinical indicators of severity.

言及状況

外部データベース (DOI)

Twitter (12 users, 14 posts, 28 favorites)

que ce passe-t-il lorsque vous activez en période épidémique l'immunité ? une production précoce de quoi ? https://t.co/fjaDOSsgSp "production précoce d'IgG anti-coronavirus 2 du syndrome respiratoire aigu sévère peut être associée à des indicateurs cliniques de gravité" Crlt
Bsr "réponse précoce de l'immunoglobuline G anti-SRAS-CoV-2 peut être associée à la gravité de la maladie chez les patients atteints de COVID-19" Aie ! Comment dire ? que fait injection ARNm et que l'on s'évertue à nous réinjecter anticorps circulants https://t.co/fjaDOSsgSp

収集済み URL リスト